Gracell Biotechnologies Other Current Liabilities

Gracell Biotechnologies (GRCL) currently reports a other current liabilities of $150M as of September 2023. That compares with $100M in the prior-year period — up 49.4% year over year. Use the charts on this page to explore Gracell Biotechnologies's other current liabilities history and peer comparisons.

Gracell Biotechnologies's other current liabilities increased from $100M to $150M — a 49.4% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Gracell Biotechnologies reported $150M in other current liabilities as of September 2023. That compares with $100M in the prior-year period — up 49.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $150M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Gracell Biotechnologies, and consider following GRCL for alerts when major investors trade the stock.

Gracell Biotechnologies is classified in the Healthcare sector. On other current liabilities, it currently shows $150M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GRCL with unrelated industries.